After a review of Portage Biotech Inc. (NasdaqCM:PRTG)'s funding requirements, the Board of Directors has made the decision to pause further drug development in the PORT-2 iNKT program. "This was a difficult decision considering the promising phase 1 safety and translational data from the non-small cell lung and melanoma trial," said Dr. Ian B. Walters, chairman and CEO, "As a result, the company will evaluate a range of potential strategic options which may include among other things, finding a partner for our iNKT program or other corporate transactions".
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.258 USD | -6.39% | -3.14% | -86.11% |
Apr. 15 | Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives | CI |
Apr. 12 | Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-86.11% | 5.45M | |
+40.62% | 54.04B | |
+45.83% | 41.96B | |
-1.94% | 41.92B | |
-7.20% | 28.35B | |
+11.62% | 26.35B | |
-21.43% | 19B | |
+5.21% | 13B | |
+29.12% | 12.28B | |
+25.34% | 12.19B |
- Stock Market
- Equities
- PRTG Stock
- News Portage Biotech Inc.
- Portage Biotech to Evaluate Range of Strategic Options